{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:31Z","timestamp":1789398331037,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cjca.2019.12.033","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:32:58Z","timestamp":1579260778000},"page":"396-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Amyloidosis as a Systemic Disease in Context"],"prefix":"10.1016","volume":"36","author":[{"given":"Sarah A.M.","family":"Cuddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.12.033_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01930815","article-title":"Ueber einem gehirn und rueckenmark des menschen auf gefundene substanz mit chemischen reaction der cellulose","volume":"6","author":"Virchow","year":"1854","journal-title":"Virchows Arch Pathol Anat"},{"key":"10.1016\/j.cjca.2019.12.033_bib2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/1831202a0","article-title":"Electron microscopic observations on a fibrous component in amyloid of diverse origins","volume":"183","author":"Cohen","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2019.12.033_bib3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 nomenclature guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.033_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.12.033_bib7","first-page":"5577","article-title":"Incidence and prevalence of light chain amyloidosis: a population-based study","volume":"130","author":"Duhamel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.12.033_bib8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.12.033_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.12.033_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cjca.2019.12.033_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib12","first-page":"665","article-title":"Amyloidosis (AL). Clinical and laboratory features in 229 cases","volume":"58","author":"Kyle","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.12.033_bib13","first-page":"383","article-title":"Treatment of chain amyloidosis (AL)","volume":"28","author":"Kyle","year":"1998","journal-title":"Adv Nephrol Necker Hosp"},{"key":"10.1016\/j.cjca.2019.12.033_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.cjca.2019.12.033_bib15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V L germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.12.033_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2019.12.033_bib17","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1681\/ASN.2006020139","article-title":"Multiple myeloma\u2014disease of the Month","volume":"17","author":"Korbet","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.12.033_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcmg.2017.08.009","article-title":"Apical to base gradient of technetium-99m pyrophosphate myocardial counts in cardiac amyloidosis","volume":"11","author":"Falk","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.12.033_bib19","first-page":"9","article-title":"Presentation and course of primary amyloidosis of the kidney","volume":"15","author":"Ogg","year":"1981","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.cjca.2019.12.033_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0303-8467(94)90022-1","article-title":"Amyloid and peripheral nervous system disease","volume":"96","author":"Haan","year":"1994","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.cjca.2019.12.033_bib21","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.033_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.cjca.2019.12.033_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0016-5107(94)70008-7","article-title":"Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein","volume":"40","author":"Tada","year":"1994","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cjca.2019.12.033_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cjca.2019.12.033_bib25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1378\/chest.124.3.969","article-title":"Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis","volume":"124","author":"Berk","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2019.12.033_bib26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.cjca.2019.12.033_bib27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1297-319X(02)00449-9","article-title":"Diagnostic tools for amyloidosis","volume":"69","author":"Hachulla","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.cjca.2019.12.033_bib28","first-page":"152","article-title":"Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials","volume":"26","author":"Gertz","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.cjca.2019.12.033_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.13805","article-title":"Recent advances in the management of AL amyloidosis","volume":"172","author":"Kastritis","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.12.033_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2019.12.033_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.12.033_bib32","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.12.033_bib33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2019.12.033_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib35","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","article-title":"Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction","volume":"36","author":"Castan\u00f5","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.12.033_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.12.033_bib37","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.12.033_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.033_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.033_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.12.033_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib45","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.033_bib46","article-title":"Afro-Caribbean heart failure in the United Kingdom","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.cjca.2019.12.033_bib47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.12.033_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/euhj.1997.0841","article-title":"A\u00a0clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy","volume":"19","author":"Hastrup Svendsen","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.12.033_bib49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)\u2013type I in Povoa do Varzim and Vila do Conde (north of Portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.cjca.2019.12.033_bib50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.cjca.2019.12.033_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.033_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1000-1","article-title":"Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series","volume":"14","author":"Waddington-Cruz","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2019.12.033_bib53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","article-title":"A\u00a0study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK","volume":"87","author":"Carr","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.033_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.033_bib55","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib56","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.033_bib57","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.12.033_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1750-3639.1996.tb00798.x","article-title":"Peripheral nerve amyloidosis","volume":"6","author":"Reilly","year":"1996","journal-title":"Brain Pathol"},{"key":"10.1016\/j.cjca.2019.12.033_bib59","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.033_bib60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.12.033_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40120-014-0023-8","article-title":"Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis","volume":"3","author":"Suhr","year":"2014","journal-title":"Neurol Ther"},{"key":"10.1016\/j.cjca.2019.12.033_bib62","first-page":"268","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cjca.2019.12.033_bib63","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.033_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/13506129.2011.623199","article-title":"Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis","volume":"18","author":"Ikeda","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.033_bib65","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/WCO.0000000000000476","article-title":"Familial amyloid polyneuropathy","volume":"30","author":"Adams","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cjca.2019.12.033_bib66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: Avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.033_bib67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/13506120208995245","article-title":"Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M)","volume":"9","author":"de Carvalho","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.033_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.TP.0000092307.98347.CB","article-title":"Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry","volume":"77","author":"Herlenius","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2019.12.033_bib72","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/lt.21817","article-title":"Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients\u2019 survival","volume":"15","author":"Okamoto","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cjca.2019.12.033_bib73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Liepnieks","year":"2007","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.033_bib74","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.033_bib75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/74082","article-title":"Rational design of potent human transthyretin amyloid disease inhibitors","volume":"7","author":"Klabunde","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.cjca.2019.12.033_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.cjca.2019.12.033_bib77","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy","volume":"310","author":"Berk","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.12.033_bib78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2019.12.033_bib79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cjca.2019.12.033_bib80","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.033_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.033_bib82","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/362553a0","article-title":"Human lysozyme gene mutations cause hereditary systemic amyloidosis","volume":"362","author":"Pepys","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2019.12.033_bib83","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ng0393-252","article-title":"Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain","volume":"3","author":"Benson","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2019.12.033_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0014-5793(90)80510-P","article-title":"Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene","volume":"276","author":"Maury","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cjca.2019.12.033_bib85","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0006-291X(88)80909-4","article-title":"Variant apolipoprotein AI as a major constituent of a human hereditary amyloid","volume":"156","author":"Nichols","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2019.12.033_bib86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2019.12.033_bib87","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell\u2013derived chemotaxin 2\u2013associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.12.033_bib88","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.12.033_bib89","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET\/CT","volume":"60","author":"Ehman","year":"2019","journal-title":"J\u00a0Nucl Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20300362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20300362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:13Z","timestamp":1760107333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X20300362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0828282X20300362"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.12.033","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloidosis as a Systemic Disease in Context","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}